PLRX
Pliant Therapeutics, Inc.
There isn't enough reported data to score PLRX yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
PLRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Strong |
PLRX's balance sheet is currently strong, but its revenue and profitability are weak. There isn't enough data to rate its cash flow.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
PLRX PE Valuation
PLRX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
PLRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect PLRX's revenue to grow, with its earnings and profitability holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
PLRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.44 | +$1.44 |
| Q2 2026 | -$1.48 | +$1.92 |
| Q1 2026 | -$1.83 | +$1.78 |
| Q4 2025 | -$2.43 | +$1.04 |
| Q3 2025 | -$2.88 | +$0.45 |
| Q2 2025 | -$3.40 | -$0.32 |
| Q1 2025 | -$3.61 | -$0.75 |
| Q4 2024 | -$3.47 | -$0.72 |
PLRX is still losing money, but far less than before: $1.44 per share over the past year, against $3.61 at its worst in early 2025.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over PLRX on earnings quality, reporting a profit while its opponent remains loss making.
PLRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $248K | -95% |
| Q1 2023 | $1.3M | +6.6% |
| Q4 2022 | $2M | -1.7% |
| Q3 2022 | $1.5M | -8% |
| Q2 2022 | $5M | +179% |
| Q1 2022 | $1.2M | -43% |
| Q4 2021 | $2M | -55% |
| Q3 2021 | $1.6M | -67% |
PLRX's revenue has slid since its 2019 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2023 | -19084% | -18490 points |
| Q1 2023 | -3160% | -902 points |
| Q4 2022 | -1903% | -673 points |
| Q3 2022 | -2156% | -472 points |
| Q2 2022 | -594% | +686 points |
| Q1 2022 | -2259% | -1205 points |
| Q4 2021 | -1231% | -805 points |
| Q3 2021 | -1684% | -1338 points |
PLRX's operating margin was −19084% last quarter, down 18490 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
PLRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17M | +$4.1M |
| Q2 2026 | -$12.8M | +$27.9M |
| Q1 2026 | -$19.2M | +$29.9M |
| Q4 2025 | -$17.8M | +$30.1M |
| Q3 2025 | -$21.1M | +$12.1M |
| Q2 2025 | -$40.7M | +$5.8M |
| Q1 2025 | -$49.1M | -$17.4M |
| Q4 2024 | -$47.9M | -$22.7M |
PLRX has burned cash in almost every quarter: −$67M over the past year, against −$159M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over PLRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
PLRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +24.7K shares |
| 1 year | +0.9% | +537K shares |
| 3 years | +3.8% | +2.3M shares |
| 5 years | +73% | +26.2M shares |
| Available history | +184% | +40.1M shares |
PLRX has 62M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | — |
| Q4 2019 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over PLRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
PLRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2020 | -2.7x | Net Cash |
| Q2 2020 | -7.4x | Net Cash |
| Q1 2020 | -4.5x | Net Cash |
PLRX has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
PLRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.9 | Oversold |
| Stochastic | 4.0 | Oversold |
PLRX's weekly RSI is 26 (oversold) and its Stochastic is 4 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
PLRX PE vs Healthcare Sector
| Metric | PLRX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PLRX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
PLRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.91 | 19% below |
| 20 week MA | $1.04 | 29% below |
| 50 week MA | $1.15 | 36% below |
| 100 week MA | $2.19 | 66% below |
| 200 week MA | $9.83 | 92% below |
PLRX is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over PLRX on trend strength, trading above more of its moving averages.
PLRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.3 | $25.4 | +14% |
| 2021 | $25.4 | $15.4 | -40% |
| 2022 | $15.4 | $18.2 | +19% |
| 2023 | $18.2 | $18.1 | -0.5% |
| 2024 | $18.1 | $13.6 | -25% |
| 2025 | $13.6 | $1.21 | -91% |
| 2026 YTD | $1.21 | $0.74 | -39% |
PLRX has finished three years in a row lower, and it's down 39% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over PLRX on returns for 2026, with the stronger performance.